Julie Catusse
Research Subjects
Julie Catusse has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Bruno Loillier
Groupe de Pharmacochimie des Récepteurs, Laboratoire Fournier SA, 50, Route de Dijon, 21121 Daix, France
3 shared publicationsDidier Pruneau
Groupe de Pharmacochimie des Récepteurs, Laboratoire Fournier SA, 50, Route de Dijon, 21121 Daix, France
3 shared publicationsJean-Luc Paquet
Groupe de Pharmacochimie des Récepteurs, Laboratoire Fournier SA, 50, Route de Dijon, 21121 Daix, France
3 shared publicationsAnne Liotard
Groupe de Pharmacochimie des Récepteurs, Laboratoire Fournier SA, 50 route de Dijon, 21121 Daix, France
2 shared publications- Marie Follo
Department of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
2 shared publications - Meike Burger
University Clinic of Freiburg, Department of Hematology and Oncology, Hugstetterstr. 55, 79106, Freiburg, Germany
2 shared publications
Latest Publications
- Open Access
Risk of stroke or myocardial infarction hospitalisation following hospitalisation for community-acquired pneumonia in Portugal: a self-controlled case series study
Objectives: We aimed to assess the risk of cardiovascular hospitalisations (stroke or myocardial infarction (MI)) following a community-acquired pneumonia (CAP) hospitalisation in a large Portuguese administrative dataset. Design: Self-controlled case series study. Setting: We used hospitalisation data from National Health Service hospitals across Portugal between 2010 and 2018. Participants: Adults hospitalised for both CAP and stroke/MI in Portugal during the 2010-2018 period (n=13 494, of which 10 400 with stroke and 3094 with MI). Primary and secondary outcome measures: We considered CAP hospitalisation as the exposure (14-, 28- and 91-day exposure periods) and acute cardiovascular (stroke or MI) hospitalisations as the outcome. Incidence rate ratios (IRR) were computed using a conditional Poisson regression (overall and by sex and age subgroups). Results: Patients were mostly male and above 75 years. Stroke/MI hospitalisation incidence was higher following CAP, compared with the baseline period. Largest differences were observed in the 14-day period after discharge (IRR for stroke: 2.55, 95% CI: 2.33–2.80; IRR for MI: 3.23, 2.78–3.75), compared with the 28-day (IRR for stroke: 2.06, 1.92–2.22; IRR for MI: 2.62, 2.32–2.95) and 91-day periods (IRR for stroke: 1.37, 1.30–1.44; IRR for MI: 1.75, 1.60–1.91). A similar trend was observed for sex and age subgroups. Conclusions: Our study shows an increased risk of stroke/MI for CAP patients, particularly during the first 2 weeks after being discharged. Effective postdischarge monitoring and follow-up, combined with efforts to prevent CAP occurrence, could improve patient outcomes.
Open AccessRisk of stroke or myocardial infarction hospitalisation following hospitalisation for community-acquired pneumonia in Portugal: a self-controlled case series study
Objectives: We aimed to assess the risk of cardiovascular hospitalisations (stroke or myocardial infarction (MI)) following a community-acquired pneumonia (CAP) hospitalisation in a large Portuguese administrative dataset. Design: Self-controlled case series study. Setting: We used hospitalisation data from National Health Service hospitals across Portugal between 2010 and 2018. Participants: Adults hospitalised for both CAP and stroke/MI in Portugal during the 2010-2018 period (n=13 494, of which 10 400 with stroke and 3094 with MI). Primary and secondary outcome measures: We considered CAP hospitalisation as the exposure (14-, 28- and 91-day exposure periods) and acute cardiovascular (stroke or MI) hospitalisations as the outcome. Incidence rate ratios (IRR) were computed using a conditional Poisson regression (overall and by sex and age subgroups). Results: Patients were mostly male and above 75 years. Stroke/MI hospitalisation incidence was higher following CAP, compared with the baseline period. Largest differences were observed in the 14-day period after discharge (IRR for stroke: 2.55, 95% CI: 2.33–2.80; IRR for MI: 3.23, 2.78–3.75), compared with the 28-day (IRR for stroke: 2.06, 1.92–2.22; IRR for MI: 2.62, 2.32–2.95) and 91-day periods (IRR for stroke: 1.37, 1.30–1.44; IRR for MI: 1.75, 1.60–1.91). A similar trend was observed for sex and age subgroups. Conclusions: Our study shows an increased risk of stroke/MI for CAP patients, particularly during the first 2 weeks after being discharged. Effective postdischarge monitoring and follow-up, combined with efforts to prevent CAP occurrence, could improve patient outcomes.
- Open Access
- 6 February 2013
- Published by Wiley in British Journal of Haematology
- Vol. 161 (1) , 104-116
Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138‐downregulation and inhibition of migration through actin depolymerization
Summary: Despite considerable advances, multiple myeloma (MM) remains incurable and the development of novel therapies targeting the interplay between plasma cells (PCs) and their bone marrow (BM) microenvironment remains essential. We investigated the effect of various agents in vitro on the proliferation, phenotype, morphology, actin polymerization and migration of MM cells and, in vivo, the tumour growth of L363‐bearing non‐obese diabetic severe combined immunodeficient mice with a deficient interleukin‐2 receptor gamma chain (NSG). In vitro, we observed a dose‐dependent cytotoxicity with bortezomib and sorafenib. Using RPMI8226 cells co‐expressing histone 2B‐mCherry and cytochrome c‐GFP, bortezomib‐ and sorafenib‐induced apoptosis was confirmed, and both agents combined showed synergism. Sorafenib induced CD138‐downregulation and abolished CXCL12‐induced actin polymerization. L363 cells expressed CCR4 and CCR5 and migrated to their common ligand CCL5. Chemotaxis to BM stroma cells was notable and significantly reduced by sorafenib. Downregulation of phospho‐ERK appeared relevant for the inhibition of actin polymerization and chemotaxis. Sorafenib alone, and combined with bortezomib, showed substantial antitumour activity in L363‐bearing NSG. Correspondingly, sorafenib induced clinical responses in MM‐/AL‐amyloidosis patients. We conclude that, in addition to the cytotoxic and anti‐angiogenic effects of sorafenib, blocking of MM cell migration and homing represent promising mechanisms to interrupt the interplay between PCs and their supportive microenvironment.
- 6 February 2013
- Published by Wiley in British Journal of Haematology
- Vol. 161 (1) , 104-116
Open AccessPotent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138‐downregulation and inhibition of migration through actin depolymerization
Summary: Despite considerable advances, multiple myeloma (MM) remains incurable and the development of novel therapies targeting the interplay between plasma cells (PCs) and their bone marrow (BM) microenvironment remains essential. We investigated the effect of various agents in vitro on the proliferation, phenotype, morphology, actin polymerization and migration of MM cells and, in vivo, the tumour growth of L363‐bearing non‐obese diabetic severe combined immunodeficient mice with a deficient interleukin‐2 receptor gamma chain (NSG). In vitro, we observed a dose‐dependent cytotoxicity with bortezomib and sorafenib. Using RPMI8226 cells co‐expressing histone 2B‐mCherry and cytochrome c‐GFP, bortezomib‐ and sorafenib‐induced apoptosis was confirmed, and both agents combined showed synergism. Sorafenib induced CD138‐downregulation and abolished CXCL12‐induced actin polymerization. L363 cells expressed CCR4 and CCR5 and migrated to their common ligand CCL5. Chemotaxis to BM stroma cells was notable and significantly reduced by sorafenib. Downregulation of phospho‐ERK appeared relevant for the inhibition of actin polymerization and chemotaxis. Sorafenib alone, and combined with bortezomib, showed substantial antitumour activity in L363‐bearing NSG. Correspondingly, sorafenib induced clinical responses in MM‐/AL‐amyloidosis patients. We conclude that, in addition to the cytotoxic and anti‐angiogenic effects of sorafenib, blocking of MM cell migration and homing represent promising mechanisms to interrupt the interplay between PCs and their supportive microenvironment.
- Open Access
- 22 November 2010
- Published by Springer Nature in Molecular Cancer
- Vol. 9 (1) , 297
Role of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia
Background: The non-signalling chemokine receptors, including receptors DARC, D6 and CCX-CKR, have recently been shown to be involved in chemokine clearance and activity regulation. The human chemokine receptor CRAM (also known as HCR or CCRL2) is the most recently identified member of this atypical group. CRAM is expressed on B cells in a maturation-stage dependent manner and absent on T cells. We have recently shown that it competitively binds CCL19. CCL19 and its signalling receptor CCR7 are critical components involved in cell recruitment to secondary lymphoid organs and in maturation. B cell Chronic Lymphocytic Leukemia (B-CLL) is a low-grade lymphoma characterized by proliferative centres (or pseudofollicles). Proliferative centres develop due to abnormal cellular localisation and they are involved in the development of malignant cells. CCR7 is highly expressed on B cells from CLL patients and mediates migration towards its ligands CCL19 and CCL21, while CRAM expression and potential interferences with CCR7 are yet to be characterized. Results: In this study, we show that B cells from patients with B-CLL present highly variable degrees of CRAM expression in contrast to more consistently high levels of CCR7. We investigated the hypothesis that, similar to the atypical receptor DARC, CRAM can modulate chemokine availability and/or efficacy, resulting in the regulation of cellular activation. We found that a high level of CRAM expression was detrimental to efficient chemotaxis with CCL19. MAP-kinase phosphorylation and intracellular calcium release induced by CCL19 were also altered by CRAM expression. In addition, we demonstrate that CRAM-induced regulation of CCL19 signalling is maintained over time. Conclusions: We postulate that CRAM is a factor involved in the fine tuning/control of CCR7/CCL19 mediated responses. This regulation could be critical to the pivotal role of CCL19 induced formation of proliferation centres supporting the T/B cells encounter as well as disease progression in B-CLL.
- 22 November 2010
- Published by Springer Nature in Molecular Cancer
- Vol. 9 (1) , 297
Open AccessRole of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia
Background: The non-signalling chemokine receptors, including receptors DARC, D6 and CCX-CKR, have recently been shown to be involved in chemokine clearance and activity regulation. The human chemokine receptor CRAM (also known as HCR or CCRL2) is the most recently identified member of this atypical group. CRAM is expressed on B cells in a maturation-stage dependent manner and absent on T cells. We have recently shown that it competitively binds CCL19. CCL19 and its signalling receptor CCR7 are critical components involved in cell recruitment to secondary lymphoid organs and in maturation. B cell Chronic Lymphocytic Leukemia (B-CLL) is a low-grade lymphoma characterized by proliferative centres (or pseudofollicles). Proliferative centres develop due to abnormal cellular localisation and they are involved in the development of malignant cells. CCR7 is highly expressed on B cells from CLL patients and mediates migration towards its ligands CCL19 and CCL21, while CRAM expression and potential interferences with CCR7 are yet to be characterized. Results: In this study, we show that B cells from patients with B-CLL present highly variable degrees of CRAM expression in contrast to more consistently high levels of CCR7. We investigated the hypothesis that, similar to the atypical receptor DARC, CRAM can modulate chemokine availability and/or efficacy, resulting in the regulation of cellular activation. We found that a high level of CRAM expression was detrimental to efficient chemotaxis with CCL19. MAP-kinase phosphorylation and intracellular calcium release induced by CCL19 were also altered by CRAM expression. In addition, we demonstrate that CRAM-induced regulation of CCL19 signalling is maintained over time. Conclusions: We postulate that CRAM is a factor involved in the fine tuning/control of CCR7/CCL19 mediated responses. This regulation could be critical to the pivotal role of CCL19 induced formation of proliferation centres supporting the T/B cells encounter as well as disease progression in B-CLL.
- Open Access
- 10 March 2010
- Published by Wiley in Immunology
- Vol. 129 (4) , 536-546
CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM‐B
Summary: The human chemokine receptor CRAM (chemokine receptor on activated macrophages), encoded by the gene CCRL2, is a new candidate for the atypical chemokine receptor family that includes the receptors DARC, D6 and chemocentryx chemokine receptor (CCX‐CKR). CRAM is maturation‐stage‐dependently expressed on human B lymphocytes and its surface expression is up‐regulated upon short‐term CCL5 exposure. Here, we demonstrate that the homeostatic chemokine CCL19 is a specific ligand for CRAM. In radioactive labelling studies CCL19 bound to CRAM‐expressing cells with an affinity similar to the described binding of its other receptor CCR7. In contrast to the known CCL19/CCR7 ligand/receptor pair, CRAM stimulation by CCL19 did not result in typical chemokine‐receptor‐dependent cellular activation like calcium mobilization or migration. Instead, we demonstrate that CRAM is constitutively recycling via clathrin‐coated pits and able to internalize CCL19 as well as anti‐CRAM antibodies. As this absence of classical chemokine receptor responses and the recycling and internalization features are characteristic for non‐classical chemokine receptors, we suggest that CRAM is the newest member of this group. As CCL19 is known to be critically involved in lymphocyte and dendritic cell trafficking, CCL19‐binding competition by CRAM might be involved in modulating these processes.
- 10 March 2010
- Published by Wiley in Immunology
- Vol. 129 (4) , 536-546
Open AccessCCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM‐B
Summary: The human chemokine receptor CRAM (chemokine receptor on activated macrophages), encoded by the gene CCRL2, is a new candidate for the atypical chemokine receptor family that includes the receptors DARC, D6 and chemocentryx chemokine receptor (CCX‐CKR). CRAM is maturation‐stage‐dependently expressed on human B lymphocytes and its surface expression is up‐regulated upon short‐term CCL5 exposure. Here, we demonstrate that the homeostatic chemokine CCL19 is a specific ligand for CRAM. In radioactive labelling studies CCL19 bound to CRAM‐expressing cells with an affinity similar to the described binding of its other receptor CCR7. In contrast to the known CCL19/CCR7 ligand/receptor pair, CRAM stimulation by CCL19 did not result in typical chemokine‐receptor‐dependent cellular activation like calcium mobilization or migration. Instead, we demonstrate that CRAM is constitutively recycling via clathrin‐coated pits and able to internalize CCL19 as well as anti‐CRAM antibodies. As this absence of classical chemokine receptor responses and the recycling and internalization features are characteristic for non‐classical chemokine receptors, we suggest that CRAM is the newest member of this group. As CCL19 is known to be critically involved in lymphocyte and dendritic cell trafficking, CCL19‐binding competition by CRAM might be involved in modulating these processes.
- 1 January 2010
- Published by S. Karger AG in Acta Haematologica
- Vol. 124 (2) , 110-114
Detection of Elevated Serum Levels of the Chemokine CCL18 in B-Cell Chronic Lymphocytic Leukaemia: Identification of a Novel Biomarker
- 1 January 2010
- Published by S. Karger AG in Acta Haematologica
- Vol. 124 (2) , 110-114
Detection of Elevated Serum Levels of the Chemokine CCL18 in B-Cell Chronic Lymphocytic Leukaemia: Identification of a Novel Biomarker
- Open Access
- 30 July 2009
- Published by Springer Nature in Journal of Inflammation
- Vol. 6 (1) , 22
CCR5 signalling, but not DARC or D6 regulatory, chemokine receptors are targeted by herpesvirus U83A chemokine which delays receptor internalisation via diversion to a caveolin-linked pathway
Background: Herpesviruses have evolved chemokines and chemokine receptors, which modulate the recruitment of human leukocytes during the inflammatory response to infection. Early post-infection, human herpesvirus 6A (HHV-6A) infected cells express the chemokine receptor U51A and chemokine U83A which have complementary effects in subverting the CC-chemokine family thereby controlling anti-viral leukocyte recruitment. Here we show that, to potentiate this activity, the viral chemokine can also avoid clearance by scavenger chemokine receptors, DARC and D6, which normally regulate an inflammatory response. Conversely, U83A delays internalisation of its signalling target receptor CCR5 with diversion to caveolin rich membrane domains. This mechanism can redirect displaced human chemokines to DARC and D6 for clearance of the anti-viral inflammatory response, leaving the viral chemokine unchecked.Methods: Cell models for competitive binding assays were established using radiolabeled human chemokines and cold U83A on CCR5, DARC or D6 expressing cells. Flow cytometry was used to assess specific chemotaxis of CCR5 bearing cells to U83A, and internalisation of CCR5 specific chemokine CCL4 after stimulation with U83A. Internalisation analyses were supported by confocal microscopy of internalisation and co-localisation of CCR5 with caveosome marker caveolin-1, after virus or human chemokine stimulation.Results: U83A displaced efficiently human chemokines from CCR5, with a high affinity of 0.01nM, but not from DARC or D6. Signalling via CCR5 resulted in specific chemoattraction of primary human leukocytes bearing CCR5. However, U83A effective binding and signalling to CCR5 resulted in delayed internalisation and recycling up to 2 hours in the absence of continual re-stimulation. This resulted in diversion to a delayed caveolin-linked pathway rather than the rapid clathrin mediated endocytosis previously shown with human chemokines CCL3 or CCL4.Conclusion: U83A diverts human chemokines from signalling, but not regulatory or scavenger, receptors facilitating their clearance, while occupying signalling receptors at the cell surface. This can enhance virus specific inflammation, facilitating dissemination to replication sensitive leukocytes while evading clearance; this has implications for linked neuro-inflammatory pathologies.
- 30 July 2009
- Published by Springer Nature in Journal of Inflammation
- Vol. 6 (1) , 22
Open AccessCCR5 signalling, but not DARC or D6 regulatory, chemokine receptors are targeted by herpesvirus U83A chemokine which delays receptor internalisation via diversion to a caveolin-linked pathway
Background: Herpesviruses have evolved chemokines and chemokine receptors, which modulate the recruitment of human leukocytes during the inflammatory response to infection. Early post-infection, human herpesvirus 6A (HHV-6A) infected cells express the chemokine receptor U51A and chemokine U83A which have complementary effects in subverting the CC-chemokine family thereby controlling anti-viral leukocyte recruitment. Here we show that, to potentiate this activity, the viral chemokine can also avoid clearance by scavenger chemokine receptors, DARC and D6, which normally regulate an inflammatory response. Conversely, U83A delays internalisation of its signalling target receptor CCR5 with diversion to caveolin rich membrane domains. This mechanism can redirect displaced human chemokines to DARC and D6 for clearance of the anti-viral inflammatory response, leaving the viral chemokine unchecked.Methods: Cell models for competitive binding assays were established using radiolabeled human chemokines and cold U83A on CCR5, DARC or D6 expressing cells. Flow cytometry was used to assess specific chemotaxis of CCR5 bearing cells to U83A, and internalisation of CCR5 specific chemokine CCL4 after stimulation with U83A. Internalisation analyses were supported by confocal microscopy of internalisation and co-localisation of CCR5 with caveosome marker caveolin-1, after virus or human chemokine stimulation.Results: U83A displaced efficiently human chemokines from CCR5, with a high affinity of 0.01nM, but not from DARC or D6. Signalling via CCR5 resulted in specific chemoattraction of primary human leukocytes bearing CCR5. However, U83A effective binding and signalling to CCR5 resulted in delayed internalisation and recycling up to 2 hours in the absence of continual re-stimulation. This resulted in diversion to a delayed caveolin-linked pathway rather than the rapid clathrin mediated endocytosis previously shown with human chemokines CCL3 or CCL4.Conclusion: U83A diverts human chemokines from signalling, but not regulatory or scavenger, receptors facilitating their clearance, while occupying signalling receptors at the cell surface. This can enhance virus specific inflammation, facilitating dissemination to replication sensitive leukocytes while evading clearance; this has implications for linked neuro-inflammatory pathologies.
- Open Access
- 19 February 2008
- Published by Wiley in European Journal of Immunology
- Vol. 38 (3) , 763-777
Immunomodulation by herpesvirus U51A chemokine receptorviaCCL5 and FOG‐2 down‐regulation plus XCR1 and CCR7 mimicry in human leukocytes
Human herpesvirus‐6A (HHV‐6A) betachemokine‐receptor U51A binds inflammatory modulators CCL2, CCL5, CCL11, CCL7, and CCL13. This unique specificity overlaps that of human chemokine receptors CCR1, CCR2, CCR3, and CCR5. In model cell lines, expression leads to CCL5 down‐regulation with both constitutive and inducible signaling. Here, immunomodulation pathways are investigated in human leukocytes permissive for infection. Constitutive signaling was shown using inositol phosphate assays and inducible calcium signaling by response to CCL2, CCL5 and CCL11. Constitutive signaling targets were examined using an immune response‐related microarray and RT‐PCR, showing down‐regulation of CCL5 and FOG‐2, a hematopoietic transcriptional repressor. By RT‐PCR and siRNA reversion, CCL5 and FOG‐2 were shown down‐regulated, during peak U51A expression post infection. Two further active ligands, XCL1 and CCL19, were identified, making U51A competitor to their human receptors, XCR1 and CCR7, on T lymphocytes, NK and dendritic cells. Finally, U51A‐expressing cell lines and infectedex vivoleukocytes, showed migration towards chemokine‐gradients, and chemokine internalization. Consequently, U51A may affect virus dissemination or host transmission by chemotaxis of infected cells to sites of chemokine secretion specific for U51A (for example the lymph node or lung, by CCL19 or CCL11, respectively) and evade immune‐effector cells by chemokine diversion and down‐regulation, affecting virus spread and inflammatory pathology.
- 19 February 2008
- Published by Wiley in European Journal of Immunology
- Vol. 38 (3) , 763-777
Open AccessImmunomodulation by herpesvirus U51A chemokine receptorviaCCL5 and FOG‐2 down‐regulation plus XCR1 and CCR7 mimicry in human leukocytes
Human herpesvirus‐6A (HHV‐6A) betachemokine‐receptor U51A binds inflammatory modulators CCL2, CCL5, CCL11, CCL7, and CCL13. This unique specificity overlaps that of human chemokine receptors CCR1, CCR2, CCR3, and CCR5. In model cell lines, expression leads to CCL5 down‐regulation with both constitutive and inducible signaling. Here, immunomodulation pathways are investigated in human leukocytes permissive for infection. Constitutive signaling was shown using inositol phosphate assays and inducible calcium signaling by response to CCL2, CCL5 and CCL11. Constitutive signaling targets were examined using an immune response‐related microarray and RT‐PCR, showing down‐regulation of CCL5 and FOG‐2, a hematopoietic transcriptional repressor. By RT‐PCR and siRNA reversion, CCL5 and FOG‐2 were shown down‐regulated, during peak U51A expression post infection. Two further active ligands, XCL1 and CCL19, were identified, making U51A competitor to their human receptors, XCR1 and CCR7, on T lymphocytes, NK and dendritic cells. Finally, U51A‐expressing cell lines and infectedex vivoleukocytes, showed migration towards chemokine‐gradients, and chemokine internalization. Consequently, U51A may affect virus dissemination or host transmission by chemotaxis of infected cells to sites of chemokine secretion specific for U51A (for example the lymph node or lung, by CCL19 or CCL11, respectively) and evade immune‐effector cells by chemokine diversion and down‐regulation, affecting virus spread and inflammatory pathology.
- 15 November 2004
- Published by Elsevier in Biochemical Pharmacology
- Vol. 68 (10) , 1947-1955
Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6
- 15 November 2004
- Published by Elsevier in Biochemical Pharmacology
- Vol. 68 (10) , 1947-1955
Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6
- 27 August 2003
- Published by Elsevier in Biochemical Pharmacology
- Vol. 66 (7) , 1171-1180
Cloning and characterization of guinea pig interleukin-8 receptor
- 27 August 2003
- Published by Elsevier in Biochemical Pharmacology
- Vol. 66 (7) , 1171-1180
Cloning and characterization of guinea pig interleukin-8 receptor
- 1 June 2003
- Published by Elsevier in Biochemical Pharmacology
- Vol. 65 (11) , 1915-1916
Erratum to “Characterization of the molecular interactions of interleukin-8 (CXCL8), growth related oncogen α (CXCL1) and a non-peptide antagonist (SB 225002) with the human CXCR2” [Biochem. Pharmacol. 65 (2003) 813–821]
- 1 June 2003
- Published by Elsevier in Biochemical Pharmacology
- Vol. 65 (11) , 1915-1916
Erratum to “Characterization of the molecular interactions of interleukin-8 (CXCL8), growth related oncogen α (CXCL1) and a non-peptide antagonist (SB 225002) with the human CXCR2” [Biochem. Pharmacol. 65 (2003) 813–821]